The findings presented here provide a platform from which to focus efforts on blocking or reversing ICAM-1-mediated adhesion to reduce cerebral malaria as well as a reconsideration of anti-CD36 strategies for controlling severe malaria. Here, CD36 is linked to cerebral malaria.